Skip to content Skip to sidebar Skip to footer

Tag: Final Analysis

national cancer institute NFvdKIhxYlU unsplash(2)

ShareFacebook TwitterLinkedinTelegramEmailClipboard

Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study

We are proud to have another publication in WM: “Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study,” (Journal of Clinical Oncology, 21/7/2023)